Search

Displaying results 3231 - 3240 of 7540 in total
  1. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides … Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based).

  2. Drug

    Coagulation factor VII human

    go.drugbank.com/drugs/DB13150
    ApprovedInvestigational

    Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000
  3. Drug

    Fedratinib

    go.drugbank.com/drugs/DB12500
    ApprovedInvestigational

    [A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090] … Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.

  4. Drug

    Lorpiprazole

    go.drugbank.com/drugs/DB09195
    Approved

    Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.

  5. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection. … This makes it useful for some types of pain that don't respond well to other opioids.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, a...

  7. Drug

    Elvitegravir

    go.drugbank.com/drugs/DB09101
    ApprovedInvestigational

    Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. … On September 24, 2014, the FDA approved the single pill form of elvitegravir.

  8. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    [L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively, for the same indication.[L49956,L49966] … [A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with

  9. Drug

    Metipranolol

    go.drugbank.com/drugs/DB01214
    ApprovedWithdrawn

    A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

    Categories: Beta Blocking Agents, Non-Selective, and Thiazides
  10. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many … rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to